
CLAIMS

What is claimed is:

1. A compound of Formula (I):



(I),



or a pharmaceutically acceptable salt thereof, wherein:

X and Z are independently O, N, or CH;

Y is NH, N, or CH;

V and W are independently N or C;

wherein at least one of X and Z is N or Y is NH;

Ring A is  or , wherein

one, two, or three of A^1, A^3, and A^4 are independently N, NR^{A1}, O, or S, and the remaining one or two of A^1, A^3, and A^4, if present, are independently CH or CR^2, wherein R^{A1} is H or C_{1-3} alkyl;

A^2 is N or C;

A^5-A^8 are independently CH, CR^2, N, or NR^{A2}, wherein at least two of A^5, A^6, A^7, and A^8 are CH or CR^2, and the remaining one or two of A^5, A^6, A^7, and A^8, if present, are N or NR^{A2}, wherein R^{A2} is =O;

wherein "*" indicates the point of attachment to V;

B^1 and B^2 are each independently N, CH or CR^B, wherein R^B is halogen;

R^1 is C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-10} cycloalkenyl, 3- to 10-membered heterocycloalkyl, -$NR^{a1}C(O)NR^{a2}R^{a3}$, -$NR^{a4}C(O)OR^{a5}$, -$NR^{a6}R^{a7}$, -$N{=}S(O)R^{a8}R^{a9}$, -OR^{a10}, -$S(O)R^{a11}$, -$S(O)(NR^{a12})R^{a13}$, -$S(O)_2NR^{a14}R^{a15}$, -$S(O)_2R^{a16}$, or -$(CR^{a17}R^{a18})_{0-1}C(O)NR^{a19}R^{a20}$,

wherein the C_1-C_6 alkyl of R^1 is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, cyano, C_{3-10} cycloalkyl, and 3- to 10-membered heterocycloalkyl optionally substituted with one or more halo; wherein the C_{3-6} cycloalkyl of R^1 is optionally substituted with one or more substituents independently selected from the group consisting of halogen; wherein the C_{3-10} cycloalkenyl of R^1 is optionally substituted with one or more substituents independently selected from the group consisting of halogen; and wherein the 3- to 10-membered heterocycloalkyl of R^1 is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C_{1-6} alkyl, and C_{1-6} haloalkyl;

R^{a1}-R^{a20} are each independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkenyl, 3- to 10-membered heterocycloalkyl, 3- to 10-membered heterocycloalkenyl, C_{6-14} aryl, or 5- to 12-membered heteroaryl, each optionally substituted with one or more substituents independently selected from the group consisting of halo, cyano, -OH, -O(C_{1-6} alkyl), C_{2-6} alkenyl, C_{3-10} cycloalkyl, -S(C_{1-6} alkyl), $=CR^{1a1}R^{1a2}$, and C_{1-6} alkyl optionally substituted with one or more substituents independently selected from the group consisting of halo, -OH, and -O(C_{1-6} alkyl), wherein R^{1a1} and R^{1a2} are each independently hydrogen or C_{1-6} alkyl; or

R^{a14} and R^{a15} are taken together with the nitrogen to which they are attached to form a 3- to 10-membered heterocycloalkyl optionally substituted with one or more halo;

each R^2 is independently halogen, C_{1-3} alkyl, C_{3-5} cycloalkyl, cyano, C_{1-3} alkyloxy, C_{3-5} cycloalkyloxy, hydroxy, or $NR^{b1}R^{b2}$, wherein the C_{1-3} alkyl of R^2 is optionally substituted by one or more substituents selected from the group consisting of -OH and oxo, and wherein R^{b1} and R^{b2} are independently C_1-C_3 alkyl or R^{b1} and R^{b2} are taken together with the nitrogen to which they are attached to form a 3- to 6-membered ring; or

R^1 and the R^2 of A^5 are taken together with the carbon atoms to which they are attached to form a C_3-C_6 cycloalkyl or a 3- to 10-membered heterocycloalkyl;

R^3 is piperidinyl, pyrrolidinyl, or azepanyl, wherein the piperidinyl, the pyrrolidinyl, or the azepanyl is optionally substituted with a C_{3-10} cycloalkyl or 3- to 10-membered heterocycloalkyl, wherein the C_{3-10} cycloalkyl or 3- to 10-membered heterocycloalkyl forms a spirocyclic or fused bicyclic ring system with the piperidinyl, pyrrolidinyl, or azepanyl, or

wherein the piperidinyl, pyrrolidinyl, or azepanyl are optionally substituted with a C_{1-2} alkylene to form a bridged piperidinyl, pyrrolidinyl, or azepanyl ring system,


wherein the piperidinyl, the pyrrolidinyl, the azepanyl, or the spirocyclic, fused, or bridged bicyclic ring system formed by the C_{3-10} cycloalkyl, 3- to 10-membered heterocycloalkyl, or C_{1-2} alkylene with piperidinyl, pyrrolidinyl, or azepanyl is optionally substituted with one or more substituents independently selected from the group consisting of C_1-C_3 alkyl, C_1-C_3 haloalkyl, and halo;


R^4 is H, halo, cyano, -OH, $-NO_2$, $-C(O)NR^{c1}R^{c2}$, $-NR^{c3}R^{c4}$, $-NR^{c5}S(O)_2R^{c6}$, $-P(O)R^{c7}R^{c8}$, $-N{=}S(O)R^{c9}R^{c10}$, $-S(O)(NR^{c11})R^{c12}$, $-S(O)_2R^{c13}$, or C_{1-6} alkyl optionally substituted with one or more substituents independently selected from the group consisting of halo and -OH,


wherein R^4 is not H when X is N, Y is N, and Z is O; and


R^{c1}-R^{c13} are each independently hydrogen, C_{3-10} cycloalkyl, or C_{1-6} alkyl, wherein each C_1-C_6 alkyl of R^{c1}-R^{c13} is optionally substituted with one or more substituents independently selected from the group consisting of halo, -OH, and -C(O)-O-C_1-C_3 alkyl, and wherein each C_{3-10} cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of C_1-C_6 alkylene-OH.


2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the ring




is 


, 

, 


, 

, 


,




3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) is a compound of Formula (I-a), (I-b), or (I-c):




(I-a),





(I-b),




(I-c).


4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring A is .


5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring A is .





, or .


6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring A is .


7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring A is .



















8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-10} cycloalkenyl, 3- to 10-membered heterocycloalkyl, $-NR^{a6}R^{a7}$, $-OR^{a10}$, $-S(O)_2NR^{a14}R^{a15}$, or $-S(O)_2R^{a16}$,


wherein the C_1-C_6 alkyl of R^1 is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, cyano, C_{3-10} cycloalkyl, and 3- to 10-membered heterocycloalkyl optionally substituted with one or more halo; wherein the C_{3-6} cycloalkyl of R^1 is optionally substituted with one or more substituents independently selected from the group consisting of halogen; wherein the C_{3-10} cycloalkenyl of R^1 is optionally substituted with one or more substituents independently selected from the group consisting of halogen; and wherein the 3- to 10-membered heterocycloalkyl of R^1 is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C_{1-6} alkyl, and C_{1-6} haloalkyl.

9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is





10. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the ring




11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^3 is piperidinyl, wherein the piperidinyl is optionally substituted with a C_{3-10} cycloalkyl or 3- to 10-membered heterocycloalkyl, wherein the C_{3-10} cycloalkyl or 3- to 10-membered heterocycloalkyl forms a spirocyclic or fused bicyclic ring system with the piperidinyl, or wherein the piperidinyl is optionally substituted with a C_{1-2} alkylene to form a bridged piperidinyl ring system, wherein the piperidinyl, or the spirocyclic, fused, or bridged bicyclic ring system formed by the C_{3-10} cycloalkyl, 3- to 10-membered heterocycloalkyl, or C_{1-2} alkylene with piperidinyl is optionally substituted with one or more substituents independently selected from the group consisting of C_1-C_3 alkyl, C_1-C_3 haloalkyl, and halo.

12. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^3 is pyrrolidinyl, wherein the pyrrolidinyl is optionally substituted with a C_{3-10} cycloalkyl or 3- to 10-membered heterocycloalkyl, wherein the C_{3-10} cycloalkyl or 3- to 10-membered heterocycloalkyl forms a spirocyclic or fused bicyclic ring system with the pyrrolidinyl, or wherein the pyrrolidinyl is optionally substituted with a C_{1-2} alkylene to form a bridged pyrrolidinyl ring system, wherein the pyrrolidinyl, or the spirocyclic, fused, or bridged bicyclic ring system formed by the C_{3-10} cycloalkyl, 3- to 10-membered heterocycloalkyl, or C_{1-2} alkylene with the pyrrolidinyl is optionally substituted with one or more substituents independently selected from the group consisting of C_1-C_3 alkyl, C_1-C_3 haloalkyl, and halo.

13. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^3 is azepanyl, the azepanyl is optionally substituted with a C_{3-10} cycloalkyl or 3- to 10-membered heterocycloalkyl, wherein the C_{3-10} cycloalkyl or 3- to 10-membered heterocycloalkyl forms a spirocyclic or fused bicyclic ring system with the azepanyl or wherein the azepanyl is optionally substituted with a C_{1-2} alkylene to form a bridged azepanyl ring system, wherein the azepanyl or the spirocyclic, fused, or bridged bicyclic ring system formed by the C_{3-10} cycloalkyl, 3- to 10-membered heterocycloalkyl, or C_{1-2} alkylene with the azepanyl is optionally substituted with one or more substituents independently selected from the group consisting of C_1-C_3 alkyl, C_1-C_3 haloalkyl, and halo.








14. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^3 is




, or .

15. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^4 is hydrogen, halo, or $-NR^{c5}S(O)_2R^{c6}$.



16. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^4 is -$NR^{c5}S(O)_2R^{c6}$.

17. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^4 is H, Br, , , , , , , or .

18. A compound of Formula (III)


(III),

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is  or , wherein

one, two, or three of A^1, A^3, and A^4 are independently N, NR^{A1}, O, or S, and the remaining one or two of A^1, A^3, and A^4, if present, are independently CH or CR^2, wherein R^{A1} is H or C_{1-3} alkyl;

A^2 is N or C;

A^5-A^8 are independently CH, CR^2, N, or NR^{A2}, wherein at least two of A^5, A^6, A^7, and A^8 are CH or CR^2, and the remaining one or two of A^5, A^6, A^7, and A^8, if present, are N or NR^{A2}, wherein R^{A2} is =O;

wherein "*" indicates the point of attachment to V;

B^1 and B^2 are each independently N, CH or CR^B, wherein R^B is halogen;

R^1 is C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-10} cycloalkenyl, 3- to 10-membered heterocycloalkyl, -$NR^{a1}C(O)NR^{a2}R^{a3}$, -$NR^{a4}C(O)OR^{a5}$, -$NR^{a6}R^{a7}$, -$N{=}S(O)R^{a8}R^{a9}$, -OR^{a10}, -$S(O)R^{a11}$, -$S(O)(NR^{a12})R^{a13}$, -$S(O)_2NR^{a14}R^{a15}$, -$S(O)_2R^{a16}$, or -$(CR^{a17}R^{a18})_{0-1}C(O)NR^{a19}R^{a20}$,

wherein the C_1-C_6 alkyl of R^1 is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, oxo, cyano, C_{3-10} cycloalkyl, and 3- to 10-membered heterocycloalkyl optionally substituted with one or more halo; wherein the C_{3-6} cycloalkyl of R^1 is optionally substituted with one or more substituents independently selected from the group consisting of halogen; wherein the C_{3-10} cycloalkenyl of R^1 is optionally substituted with one or more substituents independently selected from the group consisting of halogen; and wherein the 3- to 10-membered heterocycloalkyl of R^1 is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C_{1-6} alkyl, and C_{1-6} haloalkyl;

R^{a1}-R^{a20} are each independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkenyl, 3- to 10-membered heterocycloalkyl, 3- to 10-membered heterocycloalkenyl, C_{6-14} aryl, or 5- to 12-membered heteroaryl, each optionally substituted with one or more substituents independently selected from the group consisting of halo, cyano, -OH, -O(C_{1-6} alkyl), C_{2-6} alkenyl, C_{3-10} cycloalkyl, -S(C_{1-6} alkyl), $=CR^{1a1}R^{1a2}$, and C_{1-6} alkyl optionally substituted with one or more substituents independently selected from the group consisting of halo, -OH, and -O(C_{1-6} alkyl), wherein R^{1a1} and R^{1a2} are each independently hydrogen or C_{1-6} alkyl; or

R^{a14} and R^{a15} are taken together with the nitrogen to which they are attached to form a 3- to 10-membered heterocycloalkyl optionally substituted with one or more halo;

each R^2 is independently halogen, C_{1-3} alkyl, C_{3-5} cycloalkyl, cyano, C_{1-3} alkyloxy, C_{3-5} cycloalkyloxy, hydroxy, or $NR^{b1}R^{b2}$, wherein the C_{1-3} alkyl of R^2 is optionally substituted by one or more substituents selected from the group consisting of -OH and oxo, and wherein R^{b1} and R^{b2} are independently C_1-C_3 alkyl or R^{b1} and R^{b2} are taken together with the nitrogen to which they are attached to form a 3- to 6-membered ring; or

R^1 and the R^2 of A^5 are taken together with the carbon atoms to which they are attached to form a C_3-C_6 cycloalkyl or a 3- to 10-membered heterocycloalkyl;


wherein each R^{d1} is independently selected from the group consisting of C_1-C_3 alkyl, C_1-C_3 haloalkyl, and halo; or wherein two R^{d1} are taken together to form a C_{3-10} cycloalkyl or 3- to 10-membered heterocycloalkyl, wherein the C_{3-10} cycloalkyl or 3- to 10-membered heterocycloalkyl forms a spirocyclic or fused bicyclic ring system with the piperidinyl; or wherein two R^{d1} are taken together to form a C_{1-2} alkylene, wherein the C_{1-2} alkylene forms a bridged piperidinyl ring system,

wherein the spirocyclic, fused, or bridged bicyclic ring system formed by the C_{3-10} cycloalkyl, 3- to 10-membered heterocycloalkyl, or C_1-$_2$ alkylene with the piperidinyl is optionally substituted with one or more substituents independently selected from the group consisting of C_1-C_3 alkyl, C_1-C_3 haloalkyl, and halo;

R^4 is H, halo, cyano, -OH, -NO_2, -$C(O)NR^{c1}R^{c2}$, -$NR^{c3}R^{c4}$, -$NR^{c5}S(O)_2R^{c6}$, -$P(O)R^{c7}R^{c8}$, -$N{=}S(O)R^{c9}R^{c10}$, -$S(O)(NR^{c11})R^{c12}$, -$S(O)_2R^{c13}$, or C_{1-6} alkyl optionally substituted with one or more substituents independently selected from the group consisting of halo and -OH; and

R^{c1}-R^{c13} are each independently hydrogen, C_{3-10} cycloalkyl, or C_{1-6} alkyl, wherein each C_1-C_6 alkyl of R^{c1}-R^{c13} is optionally substituted with one or more substituents independently selected from the group consisting of halo, -OH, and -C(O)-O-C_1-C_3 alkyl, and wherein each C_{3-10} cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of C_1-C_6 alkylene-OH.

19. A compound of Formula (II):



(II**)**,



or a pharmaceutically acceptable salt thereof, wherein:

X and Z are independently O, N, or CH;

Y is NH or CH;

V and W are independently N or C;

wherein at least one of X and Z is N or Y is NH;

Ring A is  or , wherein

one or two of A^1, A^3, and A^4 are independently N, O, or S, and the remaining one or two of A^1, A^3, and A^4 are independently CH or CR^2;

A^2 is N or C;

A^5-A^8 are independently CH, CR^2 or N, wherein at least two of A^5, A^6, A^7, and A^8 are CH or CR^2, and the remaining one or two of A^5, A^6, A^7, and A^8, if present, are N;

wherein "*" indicates the point of attachment to V;

B^1 and B^2 are each independently N or CH;

R^1 is C_{1-6} alkyl, C_{3-6} cycloalkyl, 3- to 10-membered heterocycloalkyl, $-NR^{a1}C(O)NR^{a2}R^{a3}$, $-NR^{a4}C(O)OR^{a5}$, $-NR^{a6}R^{a7}$, $-N=S(O)R^{a8}R^{a9}$, $-OR^{a10}$, $-S(O)R^{a11}$, $-S(O)(NR^{a12})R^{a13}$, $-S(O)_2NR^{a14}R^{a15}$, $-S(O)_2R^{a16}$, or $-(CR^{a17}R^{a18})_{0-1}C(O)NR^{a19}R^{a20}$,

wherein the C_1-C_6 alkyl of R^1 is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, cyano, C_{3-10} cycloalkyl, and 3- to 10-membered heterocycloalkyl optionally substituted with one or more halo; wherein the C_{3-6} cycloalkyl of R^1 is optionally substituted with one or more substituents independently selected from the group consisting of halogen; and wherein the 3- to 10-membered heterocycloalkyl of R^1 is optionally substituted with one or more halogens;

R^{a1}-R^{a20} are each independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkenyl, 3- to 10-membered heterocycloalkyl, 3- to 10-membered heterocycloalkenyl, C_{6-14} aryl, or 5- to 12-membered heteroaryl, each optionally substituted with one or more substituents independently selected from the group consisting of halo, cyano, -OH, -O(C_{1-6} alkyl), C_{2-6} alkenyl, C_{3-10} cycloalkyl, -S(C_{1-6} alkyl), $=CR^{1a1}R^{1a2}$, and C_{1-6} alkyl optionally substituted with one or more substituents independently selected from the group consisting of halo, -OH, and -O(C_{1-6} alkyl), wherein R^{1a1} and R^{1a2} are each independently hydrogen or C_{1-6} alkyl;

or R^{a14} and R^{a15} are taken together with the nitrogen to which they are attached to form a 3- to 10-membered heterocycloalkyl optionally substituted with one or more halo;

each R^2 is independently halogen, C_{1-3} alkyl, C_{3-5} cycloalkyl, cyano, C_{1-3} alkyloxy, C_{3-5} cycloalkyloxy, hydroxy, or $NR^{b1}R^{b2}$, wherein R^{b1} and R^{b2} are independently C_1-C_3 alkyl or R^{b1} and R^{b2} are taken together with the nitrogen to which they are attached to form a 3- to 6-membered ring; or

R^1 and the R^2 of A^5 are taken together with the carbon atoms to which they are attached to form a C_3-C_6 cycloalkyl or a 3- to 6-membered heterocycloalkyl;

R^3 is piperidinyl, pyrrolidinyl, or azepanyl, wherein the piperidinyl, the pyrrolidinyl, or the azepanyl is optionally substituted with a C_{3-10} cycloalkyl or 3- to 10-membered heterocycloalkyl, wherein the C_{3-10} cycloalkyl or 3- to 10-membered heterocycloalkyl forms a spirocyclic or fused bicyclic ring system with the piperidinyl, pyrrolidinyl, or the azepanyl, and

wherein the piperidinyl, the pyrrolidinyl, the azepanyl or the spirocyclic or fused bicyclic ring system formed by the C_{3-10} cycloalkyl or 3- to 10-membered heterocycloalkyl with piperidinyl, pyrrolidinyl, or azepanyl is optionally substituted with one or more substituents independently selected from the group consisting of C_1-C_3 alkyl and C_1-C_3 haloalkyl;

R^4 is hydrogen, halo, cyano, -OH, -NO_2, -$C(O)NR^{c1}R^{c2}$, -$NR^{c3}R^{c4}$, -$NR^{c5}S(O)_2R^{c6}$, -$P(O)R^{c7}R^{c8}$, -$N{=}S(O)R^{c9}R^{c10}$, -$S(O)(NR^{c11})R^{c12}$, -$S(O)_2R^{c13}$, or C_{1-6} alkyl optionally substituted with one or more substituents independently selected from the group consisting of halo and -OH; and

R^{c1}-R^{c13} are each independently hydrogen, C_{3-10} cycloalkyl, or C_{1-6} alkyl, wherein each C_1-C_6 alkyl of R^{c1}-R^{c13} is optionally substituted with one or more substituents independently selected from the group consisting of halo, -OH, and -C(O)-O-C_1-C_3 alkyl.

20. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of compounds of **Table 1**.

21. A pharmaceutical composition comprising a compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.


22. An *in vitro* method of inhibiting KIF18A comprising contacting a cell with (i) an effective amount of a compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, or with (ii) a pharmaceutical composition comprising said (i) and a pharmaceutically acceptable carrier or excipient.

23. Use of a composition comprising (i) a therapeutically effective amount of a compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, or comprising (ii) said (i) and a pharmaceutically acceptable carrier or excipient, in the manufacture of a medicament for treating a disease or condition mediated by KIF18A in a subject in need thereof.

24. Use of a composition comprising (i) a therapeutically effective amount of a compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, or comprising (ii) said (i) and a pharmaceutically acceptable carrier or excipient, in the manufacture of a medicament for treating cancer in a subject in need thereof.


25. The use of claim 24, wherein the cancer is selected from the group consisting of carcinomas, cancer of the anus, bladder, breast, colon, small intestine, appendix, kidney, renal pelvis, ureter, urothelium, liver, lung, pleura, esophagus, head and neck, nasopharynx, oropharynx, hypopharynx, oral cavity, larynx, biliary tract, gall-bladder, ovary, testicle, germ cell, uterus, pancreas, stomach, cervix, thyroid, prostate, salivary gland, or skin, hematopoietic tumors of lymphoid lineage, hematopoietic tumors of myeloid lineage, hematopoietic tumors of any lineage, myeloma, tumors of mesenchymal origin including sarcomas, tumors of the central and peripheral nervous system, tumor of neuroendocrine origin, tumor of endocrine origin, small cell tumors, tumors of unknown primary, other tumors comprising retinoblastoma, melanoma, seminoma, teratocarcinoma, osteosarcoma, and other cancer-related disorders that are a consequence of cancer presence or progression.

26. A method of synthesizing the compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, the method comprising:




A

(1) contacting a compound of Formula (A) with a compound of Formula




B

(B) to produce a compound of Formula (C) or (I)




C or **I**

wherein Y is NH, X is N, and Z is N;




D

(2) converting a compound of Formula (D) to compound of Formula (A)




A ;




E

(3) converting a compound of Formula (E) to a compound of Formula




(B^a) **B^a** ;




F

(4) converting a compound of Formula (F) to a compound of Formula




(B^b) **B^b** ;




G

(5) contacting a compound of Formula (G) with a compound of Formula




H

(H) to produce a compound of Formula (J) or (I)




J or **I**

, wherein Y is NH and Z is N;




K

(6) contacting a compound of Formula (K) with a compound of Formula (L)



L




to produce a compound of Formula (M) or (I)


M or **I**

,


wherein Y is CH, X is N, Z is N, and W is N;




(7) converting a compound of Formula (C), (J), or (M) **C, J, or M** to a




compound of Formula (I) **I** ;



(8) converting a compound of Formula (C), (J), or (M) **C, J, or M** to a




compound of Formula (I) **I** ;




N

(9) converting a compound of Formula (N) to a compound of




Formula (O) **O** ;




O

(10) converting a compound of Formula (O) to a compound of




Formula (I) **I** ; or



P

(11) converting a compound of Formula (P) to a compound of



I

Formula (I) ;

or any combination of (1) to (11).

27. A composition comprising (i) a therapeutically effective amount of a compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, or comprising (ii) said (i) and a pharmaceutically acceptable carrier or excipient, for use as a medicament.